{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:30:26Z","timestamp":1778099426994,"version":"3.51.4"},"reference-count":52,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Fibroblast growth factor 21 (FGF21) is a hormone involved in regulating the metabolism, energy balance, and glucose homeostasis, with new studies demonstrating its beneficial effects on the heart. This study investigated the relationship between FGF21 levels and clinical, biochemical, and echocardiographic parameters in patients with acute coronary syndromes (ACSs). This study included 80 patients diagnosed with ACS between May and July 2023, categorized into four groups based on body mass index (BMI): Group 1 (BMI 18.5\u201324.9 kg\/m2), Group 2 (BMI 25\u201329.9 kg\/m2), Group 3 (BMI 30\u201334.9 kg\/m2), and Group 4 (BMI \u2265 35 kg\/m2). Serum FGF21 levels were measured by ELISA (Abclonal Catalog NO.: RK00084). Serum FGF21 levels were quantifiable in 55 samples (mean \u00b1 SD: 342.42 \u00b1 430.17 pg\/mL). Group-specific mean FGF21 levels were 238.98 pg\/mL \u00b1 SD in Group 1 (n = 14), 296.78 pg\/mL \u00b1 SD in Group 2 (n = 13), 373.77 pg\/mL \u00b1 SD in Group 3 (n = 12), and 449.94 pg\/mL \u00b1 SD in Group 4 (n = 16), with no statistically significant differences between groups (p = 0.47). Based on ACS diagnoses, mean FGF21 levels were 245.72 pg\/mL for STEMI (n = 21), 257.89 pg\/mL for NSTEMI (n = 9), and 456.28 pg\/mL for unstable angina (n = 25), with no significant differences observed between these diagnostic categories. Significant correlations were identified between FGF21 levels and BMI, diastolic blood pressure, and serum chloride. Regression analyses revealed correlations with uric acid, chloride, and creatinine kinase MB. This study highlights the complex interplay between FGF21, BMI, and acute coronary syndromes. While no significant differences were found in FGF21 levels between the different BMI and ACS diagnostic groups, correlations with clinical and biochemical parameters suggest a multifaceted role of FGF21 in cardiovascular health. Further research with a larger sample size is warranted to elucidate these relationships.<\/jats:p>","DOI":"10.3390\/cimb46080501","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:24:16Z","timestamp":1722957856000},"page":"8512-8525","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Connecting the Dots: FGF21 as a Potential Link between Obesity and Cardiovascular Health in Acute Coronary Syndrome Patients"],"prefix":"10.3390","volume":"46","author":[{"given":"Cristina Elena","family":"Negroiu","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200642 Craiova, Romania"},{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Lelia","family":"Riza","sequence":"additional","affiliation":[{"name":"Laboratory of Human Genomics, University of Medicine and Pharmacy of Craiova, 200638 Craiova, Romania"},{"name":"Regional Centre of Medical Genetics Dolj, Emergengy County Hospital Craiova, 200642 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Strea\u021b\u0103","sequence":"additional","affiliation":[{"name":"Laboratory of Human Genomics, University of Medicine and Pharmacy of Craiova, 200638 Craiova, Romania"},{"name":"Regional Centre of Medical Genetics Dolj, Emergengy County Hospital Craiova, 200642 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia","family":"Tudora\u0219cu","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200642 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Maria","family":"Bezn\u0103","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200642 Craiova, Romania"},{"name":"Department of Cardiology, County Clinical Emergency Hospital of Craiova, 200642 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Ionu\u021b","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"},{"name":"Department of Cardiology, County Clinical Emergency Hospital of Craiova, 200642 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0785-0123","authenticated-orcid":false,"given":"Suzana","family":"D\u0103noiu","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200642 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1161\/CIRCULATIONAHA.123.065485","article-title":"Obesity and Cardiovascular Disease: A New Dawn","volume":"149","author":"Sattar","year":"2024","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bulnes, J.F., Gonz\u00e1lez, L., Vel\u00e1squez, L., Orellana, M.P., Venturelli, P.M., and Mart\u00ednez, G. (2024). Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1356023"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology: Cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellsig.2017.08.009","article-title":"Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity","volume":"40","author":"Salminen","year":"2017","journal-title":"Cell Signal"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Spann, R.A., Morrison, C.D., and den Hartigh, L.J. (2021). The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.802541"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tillman, E.J., and Rolph, T. (2020). FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.601290"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Bookout","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tezze, C., Romanello, V., and Sandri, M. (2019). FGF21 as Modulator of Metabolism in Health and Disease. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00419"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/JOE-15-0289","article-title":"Effects of fibroblast growth factor 21 on the heart","volume":"227","author":"Tanajak","year":"2015","journal-title":"J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice","volume":"4","author":"Planavila","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cvr\/cvu263","article-title":"Fibroblast growth factor 21 protects the heart from oxidative stress","volume":"106","author":"Planavila","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2015.02.081","article-title":"FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism","volume":"459","author":"Joki","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ijo.2017.138","article-title":"Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: A marker of metabolic stress?","volume":"41","author":"Crujeiras","year":"2017","journal-title":"Int. J. Obes."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.molmet.2015.04.002","article-title":"Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes","volume":"4","author":"Berti","year":"2015","journal-title":"Mol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cen.13229","article-title":"Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes","volume":"86","author":"Woo","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1159\/000502647","article-title":"Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21","volume":"44","author":"Dziedziejko","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1210\/jc.2014-3465","article-title":"Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria","volume":"100","author":"Lee","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","article-title":"Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors","volume":"33","author":"Chow","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e015226","DOI":"10.1161\/JAHA.119.015226","article-title":"Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events","volume":"9","author":"Wu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/a-0879-2968","article-title":"Circulating FGF21 Levels in Human Health and Metabolic Disease","volume":"128","author":"Keuper","year":"2020","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.21037\/apm-21-525","article-title":"Retrospective analysis of factors associated with serum levels of fibroblast growth factor-21 in patients with diabetes","volume":"10","author":"Ren","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1210\/jc.2010-1326","article-title":"Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins","volume":"96","author":"Tyynismaa","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nakanishi, K., Ishibashi, C., Ide, S., Yamamoto, R., Nishida, M., Nagatomo, I., Moriyama, T., and Yamauchi-Takihara, K. (2021). Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02075-8"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5606\/ArchRheumatol.2019.7062","article-title":"Obesity, Echocardiographic Changes and Framingham Risk Score in the Spectrum of Gout: A Cross-Sectional Study","volume":"34","author":"Gancheva","year":"2019","journal-title":"Arch. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/HJH.0b013e328364fb58","article-title":"Left-ventricular hypertrophy and obesity: A systematic review and meta-analysis of echocardiographic studies","volume":"32","author":"Cuspidi","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pcad.2013.09.003","article-title":"Impact of obesity and weight loss on cardiac performance and morphology in adults","volume":"56","author":"Alpert","year":"2014","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Thomas, A.L., Alarcon, P.C., Divanovic, S., Chougnet, C.A., Hildeman, D.A., and Moreno-Fernandez, M.E. (2021). Implications of Inflammatory States on Dysfunctional Immune Responses in Aging and Obesity. Front. Aging, 2.","DOI":"10.3389\/fragi.2021.732414"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00481","DOI":"10.1002\/edm2.481","article-title":"Assessment of the Relationship Between Liver Enzymes and Cardiovascular Disease: A Study in Bangladeshi Adults","volume":"7","author":"Hasan","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: Mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Yan, J., Yang, N., Qian, Z., Nie, H., Yang, Z., Yan, D., Wei, X., Ruan, L., and Huang, Y. (2021). High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.705273"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cheng, J., Su, X., Qiao, L., Zhai, C., and Chen, W. (2018). Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Biosci. Rep., 38.","DOI":"10.1042\/BSR20181099"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhang, W., Chu, S., Ding, W., and Wang, F. (2015). Serum Level of Fibroblast Growth Factor 21 Is Independently Associated with Acute Myocardial Infarction. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129791"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"156591","DOI":"10.1016\/j.cyto.2024.156591","article-title":"Correlation of circulating fibroblast growth factor 21 levels with inflammatory factors and the degree of coronary artery stenosis in patients with acute myocardial infarction","volume":"178","author":"Liu","year":"2024","journal-title":"Cytokine"},{"key":"ref_43","first-page":"3024","article-title":"FGF-21: A novel biomarker predicting no-reflow in ST-segment elevation myocardial infarction","volume":"28","author":"Koprulu","year":"2024","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/mmr.2023.13133","article-title":"Insights into the relationship between serum uric acid and pulmonary hypertension (Review)","volume":"29","author":"Zhou","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: The oxidant-antioxidant paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nakayama, A., Kurajoh, M., Toyoda, Y., Takada, T., Ichida, K., and Matsuo, H. (2023). Dysuricemia. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123169"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01991","article-title":"Molecular identification of a danger signal that alerts the immune system to dying cells","volume":"425","author":"Shi","year":"2003","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V89.2.577","article-title":"The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice","volume":"89","author":"Netea","year":"1997","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3400143","article-title":"When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid","volume":"340","author":"Bagnati","year":"1999","journal-title":"Biochem. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1681\/ASN.2005050572","article-title":"Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells","volume":"16","author":"Kang","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kuwabara, M., Fukuuchi, T., Aoki, Y., Mizuta, E., Ouchi, M., Kurajoh, M., Maruhashi, T., Tanaka, A., Morikawa, N., and Nishimiya, K. (2023). Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. Biomolecules, 13.","DOI":"10.3390\/biom13101519"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","article-title":"Uric acid and cardiovascular disease","volume":"484","author":"Ndrepepa","year":"2018","journal-title":"Clin. Chim. Acta"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/8\/501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:29:36Z","timestamp":1760110176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/8\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["cimb46080501"],"URL":"https:\/\/doi.org\/10.3390\/cimb46080501","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]}}}